A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
-
Published:2024-02-02
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Coria Lorena M.ORCID, Rodriguez Juan Manuel, Demaria Agostina, Bruno Laura A., Medrano Mayra Rios, Castro Celeste Pueblas, Castro Eliana F., Del Priore Sabrina A., Hernando Insua Andres C., Kaufmann Ingrid G., Saposnik Lucas M., Stone William B., Prado Lineia, Notaro Ulises S., Amweg Ayelen N., Diaz Pablo U., Avaro Martin, Ortega Hugo, Ceballos Ana, Krum Valeria, Zurvarra Francisco M., Sidabra Johanna E., Drehe Ignacio, Baqué Jonathan A., Li Causi Mariana, De Nichilo Analia V., Payes Cristian J., Southard Teresa, Vega Julio C.ORCID, Auguste Albert J.ORCID, Álvarez Diego E., Flo Juan M.ORCID, Pasquevich Karina A.ORCID, Cassataro JulianaORCID
Abstract
AbstractIn the context of continuous emergence of SARS-CoV-2 variants of concern (VOCs), one strategy to prevent the severe outcomes of COVID-19 is developing safe and effective broad-spectrum vaccines. Here, we present preclinical studies of a RBD vaccine derived from the Gamma SARS-CoV-2 variant adjuvanted with Alum. The Gamma-adapted RBD vaccine is more immunogenic than the Ancestral RBD vaccine in terms of inducing broader neutralizing antibodies. The Gamma RBD presents more immunogenic B-cell restricted epitopes and induces a higher proportion of specific-B cells and plasmablasts than the Ancestral RBD version. The Gamma-adapted vaccine induces antigen specific T cell immune responses and confers protection against Ancestral and Omicron BA.5 SARS-CoV-2 challenge in mice. Moreover, the Gamma RBD vaccine induces higher and broader neutralizing antibody activity than homologous booster vaccination in mice previously primed with different SARS-CoV-2 vaccine platforms. Our study indicates that the adjuvanted Gamma RBD vaccine is highly immunogenic and a broad-spectrum vaccine candidate.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference41 articles.
1. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021). 2. Bos, R. et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. npj Vaccines 5, https://doi.org/10.1038/s41541-020-00243-x (2020). 3. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). 4. Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021). 5. Al Kaabi, N. et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults. JAMA 326, 35 (2021).
|
|